What is the current size and annual growth rate of the antivirals market?
The antivirals market size has grown strongly in recent years. It will grow from $106.13 billion in 2024 to $114.7 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to viral disease prevalence, public health concerns, patent expirations, government initiatives.
The antivirals market size is expected to see strong growth in the next few years. It will grow to $153.67 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to emerging viral threats, global health initiatives. Major trends in the forecast period include technological advances, telemedicine and digital health, personalized medicine.
Get Your Free Sample of The Global Antivirals Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2437&type=smp
Which major factors have contributed to the expansion of the antivirals market?
The increasing incidence of influenza is anticipated to propel the growth of the antiviral market going forward. Influenza, also called flu, is a highly contagious viral respiratory infection caused by influenza viruses that affect the nose, throat, and lungs. Antivirals are used for the treatment of influenza and are designed to inhibit the replication and spread of influenza viruses within the body. For instance, in October 2022, according to the Centers for Disease Control and Prevention, a US-based health agency, during 2021-2022 season, there were 9 million flu illnesses, 4 million flu-related medical visits, 100,000 flu-related hospitalizations, and 5,000 flu deaths. Therefore, the increasing incidence of influenza is driving the growth of the antiviral market.
How is the antivirals market segmented?
The antivirals market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other Drug classes
3) By Application: HIV, Hepatitis, Herpes, Influenza, Other Applications
Subsegments:
1) By Branded: Antivirals For HIV Or AIDS, Antivirals For Hepatitis, Antivirals For Influenza, Antivirals For Herpes Simplex Virus (HSV)
2) By Generic: Generic HIV Or AIDS Antivirals, Generic Hepatitis Antivirals, Generic Influenza Antivirals, Generic Herpes Simplex Virus (HSV) Antivirals
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report
Who are the top competitors in the antivirals market?
Major companies operating in the antivirals market include AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., AstraZeneca plc, Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Regeneron Pharmaceuticals Inc., Inovio Pharmaceuticals Inc., Novavax Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Argos Distributors Limited, AVI Biopharma International Ltd., Moderna Inc., BioNTech SE, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.
Which key trends are expected to influence the antivirals market in the coming years?
Major companies operating in the antiviral market are focusing on developing innovative treatments such as oral antiviral treatment to improve patient compliance, enhance accessibility, reduce healthcare costs, and provide more convenient and effective options for managing viral infections. Oral antiviral treatment refers to medications taken by mouth to treat viral infections. These treatments work by inhibiting the ability of viruses to replicate or spread within the body, helping to reduce the severity and duration of the infection. For instance, in May 2023, Pfizer, a US-based company that offers pharmaceuticals announced the approval of Paxlovid, marking it as the first oral antiviral treatment for COVID-19 in adults by the Food and Drug Administration, a US-based government agency. This approval is particularly significant as it provides a new therapeutic option for managing COVID-19, especially in a context where the pandemic is transitioning towards an endemic phase. Paxlovid is specifically indicated for adults with mild-to-moderate COVID-19 who are at high risk for progression to severe disease, including hospitalization or death.
Which regional trends are influencing the antivirals market, and which area dominates the industry?
North America was the largest region in the anti-viral drug therapy market in 2023. The Middle East is expected to be the fastest-growing region in the antivirals market during the forecast period. The regions covered in the antivirals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Does The Antivirals Market Report 2025 Offer?
The antivirals market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Antivirals are medications designed to treat viral infections by inhibiting the replication of viruses within the host’s cells. Unlike antibiotics, which target bacteria, antivirals are specifically used to combat viruses such as the flu, HIV, or hepatitis. They work by interfering with various stages of a virus’s lifecycle, helping to reduce the severity and duration of an infection.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2437
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
